Tom

Competitive intelligence is an extremely valuable step of any new drug or indication launch. From providing insight into a crowded market to guiding allocation of budget, this research is beneficial no matter what stage of the launch process you’re in. However, “competitive intelligence” is simply the broad, overarching term. In reality, it encompasses a variety of research tactics ranging from high-level, free information gathering to granular, high-investment research [...]

The launch of a new drug is a complex process. With so many factors playing into the final outcome, it may seem impossible to predict whether or not any given launch will be a success. While it’s true that unforeseen circumstances may impact the result of a launch — such as the start of a global pandemic — there are telling signs that can indicate launch performance. [...]

The pharma industry can be complicated, but the more intel you have – market or competitive, the better you’ll be able to make decisions that lead you to success. Understanding what’s worked for your competitors, what hasn’t, where they’re going, and what opportunities exist gives you a clear advantage — whether you’re breaking into the market or fighting to defend your market share. While these insights can be [...]

For those launching their first product, the process can be incredibly daunting – but if you know what to look for, both the successes and the failures can help guide your launch strategy. With over 215+ new product launches since our inception, we’ve got a firm grasp on what works and what doesn’t. Here are 5 key takeaways we’ve developed over the years. [...]

Historically, the management of oncology drugs in the U.S. has remained relatively hands-off, despite high budget impact. However, the situation may be changing. Recently, there has been discussion around new management tools, shifting of financial risk, and the influence of value frameworks. In June 2020, Two Labs conducted a panel with payers, hematology and oncology providers, and representatives from several big pharma and small biotech companies with oncology [...]

Launching a drug isn’t easy. All manufacturers, no matter the classification of product they create, face challenges on the journey to bring their drug to market. However, due to the nature of their dose form, complex storage needs, stability requirements, and costs, manufacturers launching specialty drugs must often navigate more hurdles than those dealing with a traditional retail product. Not appropriately planning for or inaccurately handling these hurdles [...]